DEF: Humana Outlines 2026 Annual Meeting, New Stock Plan

Humana Inc. announces its 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, executive compensation, and a new stock incentive plan, alongside a review of 2025 performance.

Summary

• The Annual Meeting of Stockholders is scheduled for Thursday, April 16, 2026, at 1:00 p.m. Eastern Time, in a virtual setting.
• Stockholders of record as of February 27, 2026, are entitled to vote on five proposals, including the election of ten director nominees, ratification of PricewaterhouseCoopers LLP as the independent auditor, a non-binding advisory vote on executive compensation, and approval of the Humana Inc. 2026 Stock Incentive Plan.
• The Board recommends voting FOR all proposals except for a stockholder proposal requesting shareholder approval for excessive golden parachutes, which the Board recommends AGAINST.
• For 2025, Humana reported full year Adjusted EPS in line with expectations and above initial guidance, demonstrating agility and resilience in a complex healthcare environment.
• Key 2025 achievements include closing over 660,000 additional gaps in care, positioning for top-quartile Stars performance, 70% of incoming members completing Health Risk Assessments, a 17% increase in user satisfaction for the online provider directory, and over 500 basis points improvement in Individual MA member retention.
• The 2025 Associate Incentive Plan (AIP) funded at 112% after the Committee applied negative discretion to align executive payouts with broader stockholder experience, despite an overall plan performance of 168.6%.
• Long-term incentives for 2025 shifted to 60% performance-based stock units (PSUs) and 40% restricted stock units (RSUs), moving away from stock options, with PSUs measured against three-year relative TSR, Stars Ratings recovery, and operational productivity goals.
• The 2023-2025 PSU Awards achieved 48.0% of target, primarily due to Adjusted EPS of $17.14, which was well below the $34.50 threshold.
• The proposed 2026 Stock Incentive Plan seeks approval for 10,800,000 shares and incorporates several corporate governance best practices, including no stock option repricing without stockholder approval and no automatic vesting upon a change in control.
• The CEO Pay Ratio for 2025 was 226:1, with the CEO's total compensation at $18,757,075 and the median employee's at $82,935.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as mixed. While operational metrics and short-term incentives show strong performance and strategic execution, the significant underperformance against long-term Adjusted EPS targets for the 2023-2025 period and the negative discretion applied to executive bonuses indicate underlying financial challenges and a need for continued recovery in shareholder value.

Positives

• Achieved full year 2025 Adjusted EPS in line with expectations and above initial guidance.
• Demonstrated strong core Medicare Advantage (MA) business performance and a focus on unlocking a stable and compelling MA margin.
• Closed over 660,000 additional gaps in care year-over-year and is positioned to regain sustainable, top-quartile Stars performance.
• 70% of incoming members completed a Health Risk Assessment before January 1, nearly doubling the previous year's number, leading to healthier members and more stable medical costs.
• Improved member service with a 17% increase in user satisfaction and a 27% increase in visit volume for the online provider directory.
• Individual MA member retention improved by more than 500 basis points since the previous year's Annual Election Period.
• Achieved strong growth across Medicaid and CenterWell businesses, which offer attractive standalone value and reinforce core strengths.
• The new 2026 Stock Incentive Plan incorporates robust corporate governance best practices, such as prohibiting stock option repricing without shareholder approval and no automatic vesting upon a change in control.
• The 2025 say-on-pay proposal received strong approval with 89% of stockholders voting in favor.
• The Compensation Committee applied negative discretion to the 2025 AIP funding rate, reducing it from 168.6% to 112%, to align executive compensation with broader stockholder experience and share price performance.

Negatives

• The 2023-2025 Performance-Based Restricted Stock Units (PSUs) achieved only 48.0% of target, primarily due to Adjusted EPS of $17.14, which was significantly below the $34.50 threshold.
• The Medicare Advantage industry faced "dynamic and challenging years" in 2023 and 2024 due to "significant and unanticipated increases in medical cost trends," which continued into 2025.
• The company's share price performance throughout 2025 was "largely impacted by these external factors," and a stockholder proposal noted the stock fell from $474 in 2020 to $252 in late 2025.
• The Compensation Committee applied negative discretion to the 2025 AIP funding rate, reducing it from 168.6% to 112%, indicating that internal performance metrics did not fully translate to desired shareholder outcomes.

Risks

• Operating in a rapidly evolving healthcare landscape characterized by complex challenges.
• Exposure to cyclical pressures within the Medicare Advantage industry.
• Navigating a complex and fragmented healthcare system for consumers.
• Operating in an increasingly competitive environment.
• Facing multifaceted risks, including a complex legal and regulatory environment and the need for robust compliance standards.
• Potential for cybersecurity threats, data privacy breaches, and the need for strong information security protocols.
• Impact of climate-related financial disclosures and environmental factors on health outcomes.
• Potential for 'excessive golden parachutes' as highlighted by a stockholder proposal, which the Board opposes.
• Reliance on government partners, such as the Centers for Medicare & Medicaid Services (CMS) and state Medicaid administrations, for program advancement.
• Volatility in the external environment impacting financial performance and earnings expectations.
• Unanticipated increases in medical cost trends, which have historically impacted earnings growth.

Future Outlook

Humana aims to sustainably and profitably grow its Medicare Advantage business over the long term by prioritizing consumer-centricity and unlocking a stable MA margin. The company plans to remain resilient and adaptable, investing in quality, access, and member experience across a range of market conditions. It will continue to innovate with government partners to advance Medicare Advantage and Medicaid programs. The proposed 2026 Stock Incentive Plan is expected to provide sufficient shares for awards for at least three to four years, supporting long-term talent attraction and retention.

Management Comments

• "The healthcare landscape in 2025 presented our Company and stakeholders with a rapidly evolving environment, characterized by complex challenges and opportunities for growth."
• "Our Company demonstrated agility and resilience by actively listening to those we serve, adapting our strategies in response to their needs and market shifts, while also fostering innovation across our enterprise."
• "Our commitment to transformation and customer-centricity has strengthened our foundation, ensuring that Humana is well-positioned to advance our vision of becoming a world-class, consumer-focused healthcare company."
• "By embracing change and continuously striving for excellence, we have built momentum that will help us achieve our purpose to help our members and patients achieve their best health."
• "Our Medicare Advantage (MA) business remains the foundation of our strategy. Despite cyclical pressures in the industry, the underlying fundamentals of the program are sound."
• "We have planned for a range of external circumstances, allowing us to prioritize consumer-centricity and unlock a stable and compelling MA margin."
• "Humanas approach is anchored in the belief that outstanding whole person care, through both our health plans and CenterWell, enables our members and patients to achieve better health outcomes. That, in turn, drives loyalty, retention, reduced medical costs, and attractive economics for the business."
• "Looking ahead, our strong foundation and differentiated capabilities position us to continue unlocking Humanas full potential as a consumer healthcare company."
• "We will remain resilient and adaptable, planning for a range of market conditions while investing in what matters most: quality, access, and member experience. We do this with a continuous commitment to not only meet regulatory standards, but to exceed them."

Industry Context

StockSavvy.ai notes that Humana's strategic emphasis on Medicare Advantage, Medicaid, and its integrated CenterWell health services aligns with broader industry trends towards value-based care, consumer-centric models, and digital health transformation. The company's efforts to address clinical outcomes and operational efficiencies are critical in a competitive U.S. healthcare market facing evolving patient needs and regulatory changes. The challenges cited in the Medicare Advantage industry due to 'unanticipated increases in medical cost trends' are consistent with pressures reported by other major health insurers during the 2023-2025 period, suggesting systemic industry-wide issues rather than solely company-specific operational failures.

Comparison to Industry Standards

• Humana's shift to a 60% performance-based stock unit (PSU) and 40% restricted stock unit (RSU) mix for long-term incentives, and the use of the Dow Jones U.S. Select Health Care Provider Index for relative Total Shareholder Return (rTSR) measurement, aligns its executive compensation practices more closely with common benchmarks observed in large-cap healthcare and managed care companies such as UnitedHealth Group Inc. and Elevance Health, Inc.
• The Compensation Committee's application of negative discretion to the 2025 Associate Incentive Plan (AIP) funding rate (reducing it from 168.6% to 112%) to align executive payouts with broader stockholder experience demonstrates a commitment to pay-for-performance principles increasingly valued by institutional investors and proxy advisors, similar to best practices seen across the industry.
• The 2023-2025 PSU achievement of only 48.0% of target, primarily due to Adjusted EPS of $17.14 falling significantly short of the $34.50 threshold, indicates underperformance relative to internal long-term targets. This suggests Humana may have lagged some industry peers in navigating the 'unanticipated increases in medical cost trends' during that period, which impacted overall financial results.

Management Changes

Corporate Governance

Legal Proceedings

• The 2025 Adjusted EPS reconciliation includes a 'Settlement of certain litigation expenses' of '$0.13', indicating a past discrete legal matter.

Related Party Transactions

• **Oracle Health**: Humana paid approximately $35,870 to Oracle Health for medical claims and services in 2025. Oracle America, Inc. (a subsidiary of Oracle Corporation, where director David T. Feinberg, M.D., serves as Chairman of Oracle Health) paid Humana Digital Health and Analytics Platform Services, Inc. (a Humana subsidiary) approximately $5.36 million in license, subscription, maintenance, and professional service fees in 2025. The Board determined these relationships were not material and did not interfere with Dr. Feinberg's independence.
• **Howard University**: Humana paid approximately $856,150 in medical claims during 2025 to the Howard University healthcare system. Wayne A. I. Frederick, M.D., a director, served as interim president and Charles R. Drew Professor of Surgery at Howard University during 2025. The Board determined this relationship was not material and did not interfere with Dr. Frederick's independence.
• **Financing Arrangements**: Certain non-employee directors are partners, shareholders, and/or officers of companies that have commercial paper programs or other financing arrangements in which Humana participates in the ordinary course of business. Payments to or from such companies constituted less than the greater of $200,000 or 1% of each of Humana's and the recipients' annual revenue, respectively, in each of the past three years. The Board determined these were not material and did not interfere with director independence.

Stakeholder Impact

• **Shareholders**: Direct impact through voting on key corporate governance matters, including director elections, auditor ratification, executive compensation, and the new stock incentive plan. Potential for long-term value creation through strategic focus on integrated care, but also exposure to industry challenges and past stock price underperformance.
• **Members and Patients**: Positive impact through improved member experiences, enhanced clinical outcomes, easier navigation to care, and a focus on high-quality, affordable, and accessible healthcare, particularly for vulnerable populations, supported by CenterWell services.
• **Employees/Associates**: Benefits from a focus on nurturing culture and engagement, competitive pay and benefits, talent development and growth opportunities, and comprehensive ethics and compliance training. The decrease in voluntary turnover rate suggests improved employee satisfaction.
• **Providers**: Enhanced collaboration with primary care physicians (PCPs) through value-based care models, aiming for improved patient outcomes, reduced hospital stays, and lower costs for Medicare Advantage members.
• **Government Partners**: Continued engagement and innovation with the Centers for Medicare & Medicaid Services (CMS) and state Medicaid administrations to advance and improve healthcare programs.
• **Communities**: Investment in local organizations, nonprofits, and civic leaders to address social and economic barriers, promote health equity, and build stronger, healthier communities.

Next Steps

• Hold the Annual Meeting of Stockholders on April 16, 2026, to vote on the proposed agenda items.
• Elect the ten director nominees named in the proxy statement.
• Ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026.
• Conduct a non-binding advisory vote to approve the compensation of the Named Executive Officers.
• Vote on the approval of the Humana Inc. 2026 Stock Incentive Plan.
• Consider and vote upon the stockholder proposal regarding shareholder approval for excessive golden parachutes.
• If approved, file a registration statement with the SEC to register the shares under the 2026 Stock Incentive Plan.
• Publish the Humana Impact Report annually in April.
• Continue to evaluate and refine management succession and leadership development planning processes.
• Engage in proactive stockholder outreach through an annual fall campaign.

Key Dates

Recommendation

The filing presents a mixed picture for investors. While Humana demonstrated strong operational execution and strategic progress in 2025, particularly in its Medicare Advantage and CenterWell segments, the significant underperformance against long-term Adjusted EPS targets for the 2023-2025 period and the Compensation Committee's application of negative discretion to executive bonuses highlight ongoing challenges in consistently translating operational success into robust shareholder value. The proposed 2026 Stock Incentive Plan and robust governance practices are positive, but the company operates in a 'complex and dynamic' industry with 'unanticipated increases in medical cost trends.' Investors should hold to observe if the strategic initiatives and improved operational efficiencies can consistently drive financial performance and shareholder returns in the coming years, especially given the past stock price decline.

Keywords

Healthcare, Medicare Advantage, Medicaid, CenterWell, Proxy Statement, Corporate Governance, Executive Compensation, Stock Incentive Plan, Financial Performance, Risk Management, ESG, Shareholder Meeting, HUM, SEC Filing